DermTech’s $143.7 Million Public Offering


Mintz served as legal counsel to DermTech, Inc.

DermTech, Inc. (NASDAQ: DMTK; DermTech), a leader in precision dermatology enabled by a non-invasive skin genomics platform, closed its $143.7 million underwritten public offering of common stock, which included the full exercise of underwriters’ option to purchase additional shares.

DermTech currently intends to use the net proceeds from the offering to fund further commercialization of its clinical commercial tests, accelerate pipeline development and for general corporate purposes, including working capital and other general and administrative purposes.

Headquartered in La Jolla, California, DermTech is the leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by its non-invasive skin genomics platform. The company’s mission is to transform dermatology with its non-invasive skin genomics platform, to democratize access to high quality dermatology care, and to improve the lives of millions. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. The company also markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments.

The Mintz team advising DermTech was led by Member and Co-chair of the Venture Capital & Emerging Companies Practice Jeremy Glaser (Picture), and included Member Melanie Ruthrauff Levy and Associates Peter Cunningham and Jason Miller.

Involved fees earner: Peter Cunningham – Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo; Jeremy Glaser – Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo; Melanie Ruthrauff Levy – Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo; Jason Miller – Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo;

Law Firms: Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo;

Clients: DermTech;

Author: Ambrogio Visconti